1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Suven Life Sciences Limited

Suven Life Sciences Limited

268.20
INR
-10.45
(-3.75%)
-15.07EPS
79.30BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
40.25
39.92
36.16
38.97
44.35
19.97
1.04
0.98
0.88
0.62
0.54
0.31
0.31
0.38
Basic EPS, GAAP
11.37
8.33
5.2
6.31
8.95
-1.73
-6.82
-5.22
-9.05
-5.42
-4.82
-7.37
-12.13
-15.07
Free Cash Flow per Basic Share
6.57
1.89
0.7
5.69
2.04
-6.68
-9.92
-7.41
-10.93
-5.45
-3.79
-8.78
-13.46
- -
Dividend per Share
0.32
2.62
2.88
0.92
1.66
1.67
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
20.86
40.81
43.1
48.29
55.56
17.31
10.38
7.82
6.09
17.21
12.38
5.04
22.43
- -
Tangible Book Value per Share
20.86
40.79
43.07
48.2
55.36
17.31
10.37
7.81
6.08
17.2
12.37
5.04
22.42
- -
Basic Weighted Avg Shares
127
130
138
138
138
138
138
138
135
218
218
218
228
234
Sales/Revenue/Turnover
5,103
5,209
4,995
5,382
6,126
2,758
144
135
118
135
117
67
71
88
Operating Margin (%)
41.19
28.64
12.08
20.24
28.92
-8.99
-828.1
-616.99
-1,064.46
-974.35
-1,148.52
-2,572.93
-4,072.23
-4,228.11
Depreciation Expense
115
242
240
276
248
142
40
35
36
58
58
53
56
64
Net Income, GAAP
1,442
1,088
718
872
1,237
-239
-942
-722
-1,220
-1,183
-1,051
-1,607
-2,763
-3,524
Effective Tax Rate (%)
28.89
28.24
26.37
29.16
36.74
15,423.14
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
28.25
20.88
14.38
16.2
20.19
-8.67
-653.62
-535.31
-1,029.99
-873.52
-898.62
-2,415.11
-3,884.13
-3,998.7
Working Capital
1,255
3,309
3,170
3,731
4,480
2,413
395
868
583
2,405
2,432
520
5,280
- -
LT Debt
377
594
416
259
22
18
40
27
16
6
- -
- -
121
- -
Total Equity
2,644
5,637
5,953
6,670
7,674
2,391
1,433
1,080
961
3,753
2,700
1,100
5,914
- -
Return on Invested Capital (%)
51.8
21.22
6.56
10.9
14.56
728.13
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
51.48
22.14
11.1
12.69
16.3
-39.85
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
68.83
26.26
12.4
13.81
17.25
-4.75
-49.27
-57.41
-119.51
-50.17
-32.56
-84.6
-78.8
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
45
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
121
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
227
264
283
Market Capitalization
37,822
34,732
79,301

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
5,467
- -
Cash, Cash Equivalents & STI
- -
1,889
- -
Accounts Receivable, Net
- -
15
- -
Inventories
- -
1
- -
Total Current Liabilities
- -
188
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
45
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
52.33%
125.95%
437.7%
Free Cash Flow
43.29%
37.19%
60.15%
Net Income, GAAP
39.44%
35.95%
71.91%
Sales/Revenue/Turnover
-18.23%
-9.53%
6.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
10
26
16
15
67
2026
19
9
28
15
71
2027
36
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-1.29
-2.27
-1.79
-2.02
-7.37
2026
-2.36
-3.48
-4.55
-2.02
-12.13
2027
-4.84
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Venkateswarlu Jasti
Full Time Employees
181
Sector
Health technology
Industry
Pharmaceuticals: major
Address
8-2-334, SDE Serene Chambers Hyderabad TS India 500034
IPO Date
Mar 6, 1995
Website
suven.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company incorporated in 1989 and headquartered in Hyderabad, India, engages in the discovery, development, and commercialization of novel therapeutics targeting neurodegenerative disorders, with a primary focus on central nervous system (CNS) therapies including molecules for cognitive impairments such as Alzheimer's disease, dementia, narcolepsy, and delirium. The company provides comprehensive drug discovery and development support services to global pharmaceutical and biotechnology firms; offers contract research and manufacturing services encompassing synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME studies, pharmacology, toxicology, and clinical supplies manufacturing including formulations like tablets, capsules, injectables, and ophthalmics; and develops new chemical entities (NCEs) alongside generic product development, novel drug delivery systems (NDDS), and regulatory management. Operations span India with state-of-the-art facilities in Hyderabad and export activities to international markets including North America and Europe. In recent developments, the company pursues strategic fundraising through warrants issuance closed in July 2025 involving investors such as Jasti Family Trust, Quant Mutual Fund, and others; advances a merger with Suven Pharmaceuticals (rebranded as Cohance Lifesciences) approved by NCLT in March 2025 to create a technology-driven contract development and manufacturing organization (CDMO) platform across antibody drug conjugates, oligonucleotides, and small molecules, targeting over $1 billion in revenue within five years; and supports related expansions through acquisitions like Sapala Organics in June 2024 for oligonucleotide capabilities and NJ Bio in December 2024 for antibody-drug conjugate development.